Development and investigation of a free and informed choice process for embryo donation to stem cell research in Canada.

J Obstet Gynaecol Can

Department of Obstetrics and Gynaecology, Schulich School of Medicine & Dentistry, University of Western Ontario, London ON.

Published: October 2006

Objectives: To develop and investigate a consent process that satisfies the Assisted Human Reproduction (AHR) Act and the Canadian Institutes of Health Research (CIHR) Stem Cell Guidelines, furthers free and informed choice, and fosters embryo donation to human embryonic stem cell (hESC) research.

Methods: Consultations were undertaken with an hESC scientist, in vitro fertilization (IVF) team members, and the ethicist-author of the CIHR Guidelines to review the AHR Act, the CIHR Stem Cell Guidelines, the established consent process for embryo donation at University Hospital, London Health Sciences Centre, the characteristics of patients appropriate for contact, and strategies for sensitive recruitment. Invitation-to-participate packages were sent to patients.

Results: Patients deemed appropriate for contact had indicated their intent to donate embryos to research, had embryos that had been cryopreserved for more than five years, had not received donor gametes, and had publicly listed addresses, with no suggestion of separation of the parties. Strategies developed to promote anonymity, confidentiality, and informed choice included a "firewall" between clinical and research teams and documents reiterating that, if embryos were donated, the woman would have to undergo additional IVF treatment to have a child. Of 40 couples contacted, only 22 agreed to donate embryos to the hESC study. One couple no longer wished to donate embryos to research, one package was returned as undeliverable, and no response was received from 16 couples.

Conclusions: The consent requirements of the AHR Act and the CIHR Stem Cell Guidelines should be met. Consider delaying the request for final consent until a significant time after IVF treatment to ensure that patients no longer want their embryos for reproductive purposes and are free from perceptions of coercion. A consent process promoting free and informed choice, sensitive recruitment, and donation of embryos for hESC research should be developed by the Canadian professional bodies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1701-2163(16)32279-4DOI Listing

Publication Analysis

Top Keywords

stem cell
20
informed choice
16
free informed
12
embryo donation
12
consent process
12
cihr stem
12
cell guidelines
12
donate embryos
12
process embryo
8
ahr cihr
8

Similar Publications

The Transformative Role of Artificial Intelligence in Dentistry: A Comprehensive Overview. Part 1: Fundamentals of AI, and its Contemporary Applications in Dentistry.

Int Dent J

March 2025

Department of Restorative Dentistry, College of Dentistry, Ajman University, Ajman, United Arab Emirates; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.

Artificial intelligence (AI) holds immense promise in revolutionising dentistry, spanning, diagnostics, treatment planning and educational realms. This narrative review, in two parts, explores the fundamentals and the multifaceted potential of AI in dentistry. The current article explores the profound impact of AI in dentistry, encompassing diagnostic tools, treatment planning, and patient care.

View Article and Find Full Text PDF

Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination.

View Article and Find Full Text PDF

A reflection on Arnold Caplan, the father of MSC.

Best Pract Res Clin Haematol

December 2024

Departments of Pathology, Biomedical Engineering, and Macromolecular Science, Case Western Reserve University, USA. Electronic address:

Arnold Caplan was the father of MSC, mesenchymal stem cells. His pioneering efforts have led to significant advances in the utilization of mesenchymal stem cells for the treatment of a wide variety of clinical diseases. This reflection provides some insight into Arnold's commitment to education and research regarding mesenchymal stem cells.

View Article and Find Full Text PDF

Cytokines in hematopoietic cell transplantation and related cellular therapies.

Best Pract Res Clin Haematol

December 2024

Division of Hematology/Oncology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, USA; Columbia Center for Translational Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York City, USA. Electronic address:

Cytokines are pleiotropic molecules involved in hematopoiesis, immune responses, infections, and inflammation. They play critical roles in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies, mediating both therapeutic and adverse effects. Thus, cytokines contribute to the immunopathology of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).

View Article and Find Full Text PDF

Cytokine therapy of acute radiation syndrome.

Best Pract Res Clin Haematol

December 2024

Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, SW7 2AZ, UK.

Radiological accidents/incidents are common with nearly 400 reported since 1944 exposing about 3000 people to substantial doses of ionizing radiations with 127 deaths. Damage to hematopoietic stem and progenitor cells with resulting bone marrow failure is a common consequence of exposure to whole body acute high-dose and -dose-rate ionizing radiations and is termed hematopoietic-acute radiation syndrome, or H-ARS. Therapy of H-ARS includes transfusions, anti-bacterial and -viral drugs, molecularly-cloned hematopoietic growth factors and hematopoietic cell transplants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!